Pricing Log in Create free account
Friday 6 November 2026 Export DCTH’s income statement to Excel — free account

Delcath Systems, Inc.

DCTH Healthcare Medical Devices

Delcath Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 129.1% from fiscal 2024.

Revenue
+20.6%
EPS
−12.5%
Free cash flow
−24.5%

Quarter to June 2026, against a year earlier

14.92 0.43 +2.97%
Market cap
$502.8M
P/E
1,455×
Fwd P/E
−93.6×
Dividend yield
—
F-score
7/9
Altman Z
13.26
Beneish M
−2.73
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.05
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 10.57%

Capital & Financial Ratios $m

Size
Market Cap 502.79
Revenue ttm 95.42
Net income ttm 0.53
Free cash flow ttm 17.51
Net debt Q (95.90)
Valuation
P/E 1,455.00 (above 35: high)
Forward P/E (93.60) (negative: loss-making)
Price / sales 5.47
Forward P/S Powerpack
Price / FCF 29.83
Price / book 4.31
Financial health
Current ratio Q 9.83 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 1.03
Growth
Revenue growth Q +20.60% (above 0%: growing)
Operating income growth Q −7.53% (below 0%: shrinking)
EPS, this year −358.03% (below 0%: weak)
EPS, next year A +66.51% (at or above 15%: strong)
Revenue, next year A +24.60% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +37.00% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.5×, against a ten-year median of 7.8×; over the ten years it ranged from −8.8× in 2017 to 556,291,208× in 2016.
P/S against its own 10 years 31.06%
10-year low 10-year high
P/B against its own 10 years 40.94%
10-year low 10-year high
EV/Sales against its own 10 years 27.62%
10-year low 10-year high
EV/FCF against its own 10 years 82.25%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 33 53 91 96
Receivables 0 11 12 16
Inventory 3 7 10 12
Other — — — —
37 74 120 131
2023 2024 2025 Q'26
Payables 1 1 3 4
ST’ Debt — — — —
Other — — — —
16 6 11 13

Compound Annual Growth %

10y 5y 3y
Sales 47.51% 120.21% 215.30%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 29.17% 38.18% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.16 Actual 0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.02 0.02 Met by 0.00
Q4 FY25 −0.06 −0.05 Beat by 0.01
Q1 FY26 −0.01 −0.03 Miss by 0.02
Q2 FY26 −0.16 0.07 Beat by 0.23
Q3 FY26 −0.10 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.03) 0.07 — — —
’25 0.03 0.07 0.02 (0.05) 0.07
’24 (0.45) (0.48) 0.06 (0.11) (0.93)
’23 (0.77) (0.58) (1.14) (0.48) (2.94)
’22 (1.00) (1.18) (0.92) (0.86) (4.12)
’21 (1.04) (0.96) (0.94) (0.69) (3.59)
’20 (108.07) (1.90) (1.16) (0.61) (8.35)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 25 29 — — —
’25 20 24 21 21 85
’24 3 8 11 15 37
’23 1 0 0 1 2
’22 0 1 1 1 3
’21 0 1 1 2 4
’20 0 0 0 1 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1 6 — — —
’25 2 7 5 8 23
’24 (10) (4) (4) (1) (19)
’23 (4) (10) (9) (8) (31)
’22 (6) (6) (5) (7) (25)
’21 (5) (7) (5) (6) (23)
’20 (5) (8) (5) (5) (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 5 — — —
’25 2 7 4 8 21
’24 (10) (5) (4) (1) (19)
’23 (4) (10) (9) (8) (31)
’22 (6) (6) (5) (7) (25)
’21 (5) (7) (5) (6) (23)
’20 (5) (8) (5) (5) (24)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 3 3 2 2 4 3 2 37 85 95 +51.8% 106 132 157 +22.6%
Gross margin, % 72.39 74.18 70.38 54.49 61.12 81.13 74.77 69.25 83.37 86.16 87.05 +13.8 pt
EBT (18) (45) (19) (9) (24) (26) (37) (48) (26) 4 1 n/m
EBT margin, % (902.16) (1,661.77) (564.19) (561.96) (1,467.56) (721.49) (1,342.70) (2,308.86) (70.92) 4.12 1.35 +906.3 pt
Net income (18) (45) (19) (9) (24) (26) (37) (48) (26) 3 1 n/m
Per share, $
Per share, $ Revenue 415.00 0.00 89.19 61.00 0.57 0.50 0.31 0.13 1.30 2.38 2.66 (43.6%)
Earnings (3,707.65) (2,275,875.00) (514.29) (342.82) (8.35) (3.59) (4.12) (2.94) (0.93) 0.08 0.01 n/m
Cash flow (2,961.04) 0.00 (385.65) (914.63) (7.89) (3.16) (2.81) (1.93) (0.66) 0.63 0.55 n/m
Capex (53.75) 0.00 (1.99) (0.93) (0.27) (0.02) (0.02) 0.00 (0.02) (0.04) (0.06) (54.7%)
Free cash flow (3,014.79) 0.00 (387.64) (915.56) (8.16) (3.18) (2.84) (1.93) (0.67) 0.59 0.49 n/m
Book value (310.42) 0.00 (391.07) (245.44) 7.62 1.67 (0.66) 0.97 2.41 3.10 3.38 n/m
Shares, m 0 0 0 0 3 7 9 16 29 36 36 +169.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 126.25 1,455.00 12.6
P/S 256,215.11 0.00 2.20 0.35 31.55 15.58 11.28 32.30 9.23 4.24 5.47 25,632.2
P/B 0.00 0.00 0.00 0.00 2.35 4.63 0.00 4.23 4.99 3.25 4.31 1.9
EV/Sales 256,202.42 0.40 1.18 (4.83) 14.35 12.22 9.82 17.53 7.85 3.20 4.49 25,626.4
EV/FCF (35,267.45) (0.07) (0.27) 0.32 (1.00) (1.91) (1.06) (1.16) (15.18) 13.01 24.47 (3,527.5)
Cash, $m
Cash, $m Operating cash flow (14) (15) (15) (24) (23) (23) (25) (31) (19) 23 20 n/m
Capex 0 (1) 0 0 (1) 0 0 0 (1) (2) (2) +22.0%
Free cash flow (14) (16) (15) (24) (24) (23) (25) (31) (19) 21 18 n/m
Balance, $m
Balance, $m Working capital (2) 0 (12) (3) 22 25 1 21 68 109 117 n/m
Net debt (32) (5) (4) (8) (28) (12) (4) (33) (53) (91) (96) +12.4%
Shareholders’ equity (1) 1 (15) (6) 22 12 (6) 16 69 111 121 n/m
Returns, %
Returns, % ROA (70.51) (206.88) (244.38) (84.34) (99.13) (75.71) (143.21) (168.85) (45.81) 2.70 0.42 +73.2 pt
ROIC 0.00 0.00 0.00 0.00 0.00 (153,318.75) 0.00 0.00 (50.00) 2.04 (4.49) +2.0 pt
ROE (505.44) 11,242.36 269.57 83.39 (308.01) (150.74) (1,198.36) (961.44) (62.44) 3.00 0.47 +508.4 pt
People
People Employees 43 46 43 33 36 55 52 76 96 156 — +15.4%
Revenue/emp, $m 0.05 0.06 0.08 0.05 0.05 0.06 0.05 0.03 0.39 0.55 — +31.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Delcath Systems, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AVR Anteris Technologies Global Corp. $544.0M — (loss-making) — +63.27% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.91% (3,072.05%) Compare
SGHT Sight Sciences, Inc. $537.7M — (loss-making) — (loss-making) +25.20% (above 0%: growing) n/m +72.21% (above 0%: growing) 85.94% (24.59%) Compare
DCTH Delcath Systems, Inc. $502.8M 1,455× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22%
NPCE NeuroPace, Inc. $435.6M — (loss-making) — (loss-making) −2.95% (below 0%: shrinking) n/m −78.70% (below 0%: shrinking) 82.83% (22.53%) Compare
CERS Cerus Corporation $430.2M — (loss-making) — (loss-making) +6.28% (above 0%: growing) n/m +2,471.28% (above 0%: growing) 57.12% 0.60% Compare
BWAY Brainsway Ltd. Sponsored ADR $427.1M 21.2× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
SENS Senseonics Holdings, Inc. $422.5M — (loss-making) — (loss-making) +117.82% (above 0%: growing) n/m −223.24% (below 0%: shrinking) 59.10% (248.48%) Compare
MASS 908 Devices Inc. $419.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
SSII SS Innovations International, Inc. $380.9M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
Median of peers $428.6M — — +30.32% — −11.73% 66.86% (23.56%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 2 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.77m 3.11m 280.56
2024 2.16m 4.88m 334.44
2023 2.52m 2.15m 115.56
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Delcath Systems, Inc. (DCTH) Latest News

19 Oct

Impact 4 · · Business Wire

11 Sep

Impact 3 ·

6 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

14 Jul

Impact 4 ·

9 Jul

Impact 3 ·

8 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby transcript

7 May

Impact 4 · · MarketBeat
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Zacks

1 May

Impact 4 · · Simply Wall St.

6 Apr

Impact 4 · · Business Wire

4 Mar

Impact 4 · · TipRanks

3 Mar

Impact 4 · · Business Wire

26 Feb

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 4 ·

15 Feb

Impact 3 · · Simply Wall St.

12 Feb

Impact 3 · · Business Wire

11 Feb

Impact 4 · · Insider Monkey

25 Jan

Impact 4 · · Simply Wall St.

9 Jan

Impact 4 · · Business Wire

4 Jan

Impact 4 ·

2 Jan

Impact 3 · · Zacks

1 Jan

Impact 3 · · TipRanks
stockrow.com/DCTH · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com